Design of randomized phase 3 trials. A, ASPIRE trial; B, ENDEAVOR... | Download Scientific Diagram
Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
ASPIRE Trial - KRd VS Rd - Multiple Myeloma Clinical Trials
Carfilzomib in multiple myeloma
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial | PLOS Medicine
Advances in the Treatment of Multiple Myeloma: Next-Generation Proteasome Inhibition
Final ASPIRE Results Confirm Survival Benefit With Carfilzomib Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Elotuzumab - A Closer Look At The ELOQUENT-2 Clinical Trial Results
![The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The](https://www.thelancet.com/cms/attachment/2f9746ff-a56a-4d1f-9fa7-5e6b9f11a6ee/gr1_lrg.jpg "The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The")
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The
Carfilzomib Benefits Outweigh Potential for Cardiac Toxicity in Relapsed/Refractory Myeloma
PFS in KRd patients: ≥CR responders versus | Download Scientific Diagram
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment | Blood Cancer Journal
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Patient characteristics of 130 relapse and refractory multiple myeloma... | Download Scientific Diagram
OS of Aspire Study. (7) | Download Scientific Diagram
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Carfilzomib in multiple myeloma
Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial | PLOS Medicine
